- AM09: Transcriptomic Point of Departure (tPOD): Basics to Bioinformatic Considerations
-
Primary Endorser: Molecular and Systems Biology Specialty Section
Endorser(s): Regulatory and Safety Evaluation Specialty Section
Endorser(s): Risk Assessment Specialty Section
Traditionally in toxicology, whole animal studies are designed to identify a dose at which no adverse effects are likely to occur for humans or species of concern. These reference doses are extrapolated from no-adverse-effect levels or benchmark doses (BMDs) that are used as a point of departure (POD). Transcriptomic dose-response modeling is a promising method that can produce PODs from gene expression profiling. A transcriptomic POD (tPOD) represents the lowest dose at which there is a detectable concerted change in gene expression in response to chemical exposure. At exposure levels below this tPOD, the likelihood of experiencing adverse toxicological effects is minimal. The tPOD is thought to be highly predictive of potential adverse toxicological effects that can be induced by a chemical stressor, making it a potentially valuable tool in risk assessment. Regulatory bodies are starting to consider the use of tPOD frameworks, like the US EPA’s Transcriptomics Assessment Product (ETAP) and Health Canada’s exploration of the use of tPODs with in vitro approaches.
In this course, participants will learn the scientific basis of why tPODs are appropriate for use in chemical risk assessment, including the biological rationale that coordinated changes in gene expression represent early indicators of cellular perturbation that precede overt adverse outcomes. These transcriptomic responses reflect the activation of stress response pathways, adaptive mechanisms, and toxicity pathways that are well established in mechanistic toxicology. Because these changes occur at doses lower than those causing apical effects, tPODs provide a sensitive and protective point of departure that aligns with the goal of identifying thresholds for potential harm. Participants will also learn how tPODs fit into current regulatory paradigms and how they compare to traditional apical PODs. The course will cover the key steps required to calculate a tPOD, including study design considerations such as dose spacing and replicate number, upstream data processing steps following sequencing such as outlier detection and removal, and downstream analytical decisions related to transcriptomic data filtering and model fitting. Finally, approaches for deriving a transcriptome-wide tPOD will be discussed, including comparisons between distribution-based and gene set-based methods, along with practical considerations for interpretation and application in risk assessment contexts.
This course is aimed at a wide audience, from those who have heard of a tPOD but are unfamiliar with the steps needed to calculate them to those who are seasoned bioinformaticians but want to learn about current best practices based on recent research. For attendees interested in performing tPOD estimation themselves, BMDExpress files containing a completed analysis will be made available before the meeting. Some lectures will use this file to contextualize analysis settings as they appear in the software. However, attendees will not be required to perform a live analysis in BMDExpress during or prior to the course. The course is structured progressively, beginning with foundational concepts and regulatory context before moving into more technical bioinformatic and analytical considerations, ensuring accessibility for attendees with varying levels of transcriptomics expertise. Each talk will introduce a topic, showcase studies with publicly available data, and provide recommendations on process or practices to avoid.
Learning Objectives: After completing this course, participants will be able to: 1. Describe the biological and regulatory rationale for using transcriptomic points of departure (tPODs) in chemical risk assessment. 2. Identify key study design considerations that influence the reliability and interpretability of transcriptomic dose-response analyses. 3.Evaluate the impact of upstream data processing and quality control decisions on transcriptomic benchmark dose modeling results. 4. Compare approaches for filtering, modeling, and aggregating gene-level benchmark dose data during tPOD derivation. 5. Distinguish between distribution-based and gene set-based approaches for deriving transcriptome-wide tPODs and discuss their applications in risk assessment.Session and Activity Type
Enter Note
Go to previous page in this tab
Event
